Organogenesis Applauds Findings from the Office of Inspector General
Organogenesis Holdings Inc. (ORGO) recently welcomed the U.S. Office of the Inspector General's findings, which indicate that transitioning skin substitute products to average sales price (ASP)-based payments could significantly reduce Medicare Part B expenditures. The report noted that the Centers for Medicare and Medicaid Services (CMS) could save tens of millions of dollars quarterly by adopting this methodology. CEO Gary S. Gillheeney emphasized the potential for improved access to effective treatments and a more stable market for skin substitutes. The company urges CMS to publish ASPs for all skin substitutes in the coming year.
- Potential Medicare savings of tens of millions per quarter through ASP-based payments.
- Improved access to efficacious treatment options such as human cell and tissue-based products.
- Stabilization of the skin substitute market promoting fair competition.
- None.
Transitioning all skin substitutes to ASP-based payments has the potential to substantially reduce Medicare Part B expenditures
CANTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the findings by the Office of the Inspector General (OIG) of the U.S. Department of Health and Human Services (HHS) that transitioning all skin substitute products to average sales price (ASP) -based payments has the potential to substantially reduce Medicare Part B expenditures.
In the report, entitled “Some Skin Substitute Manufacturers Did Not Comply with New ASP Reporting Requirements,” OIG concluded Centers for Medicare and Medicaid Services (CMS) could potentially save tens of millions of dollars per quarter if it uniformly used the ASP payment methodology for all skin substitutes.
“CMS has made progress in the last six months by expanding the number of skin substitutes that are being paid on the basis of ASP,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “Transitioning all skin substitutes to ASP-based payments should improve access to more efficacious treatment options such as human cell and tissue-based products (HCT/Ps), and according to the report, lower the cost to the Medicare trust fund.” Gillheeney added, “ASP-based payments are an important step in stabilizing the skin substitute market and creating a level-playing field. This complements the previous action by the FDA requiring certain injectable tissue products be taken off the market and proceed down a biologics license application (BLA) pathway.”
“Organogenesis is committed to providing access to our portfolio of products across the continuum of care – including physicians’ offices and strongly urges CMS to publish ASPs for all skin substitutes this year,” Gillheeney concluded.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.
FAQ
What is Organogenesis Holdings Inc.'s stance on ASP-based payments?
How much could CMS save by implementing ASP-based payments for skin substitutes?
What are the benefits of ASP-based payments for Organogenesis Holdings?
When does Organogenesis hope to see ASPs published for skin substitutes?
What is the focus of Organogenesis Holdings Inc.?
